As these pressures increase, OXB supports developers through viral vector manufacturing and process development spanning early-stage programmes through commercial supply. It is a quality and innovation-led cell and gene therapy CDMO providing end-to-end services from preclinical development through commercial launch. More than 85 client programmes, over 1,000 GMP batches and upwards of 45 regulatory submissions reflect the operational scale supporting its activities.
Originally established as a spinout from the University of Oxford, OXB has developed capabilities around lentiviral vector manufacturing and broader viral vector technologies used in advanced therapies. The company’s work spans process development, analytical support, GMP manufacturing and regulatory support for cell and gene therapy developers operating across multiple therapeutic areas.
Integrated Viral Vector Production
Manufacturing consistency remains one of the central operational challenges in cell and gene therapy. Viral vector production requires alignment between upstream processing, purification, analytics and fill-finish activities, particularly as therapies move into larger patient populations and commercial manufacturing volumes. OXB integrates these activities through platform-based manufacturing systems developed for lentiviral and adeno-associated viral vectors.
Its LentiVector™ platform combines vector design, upstream and downstream processing, analytical testing and GMP manufacturing within a unified production structure. The platform incorporates technologies including suspension and perfusion processes, scalable producer cell lines and proprietary vector systems intended to improve productivity, purity and manufacturing reproducibility.
Operational flexibility has become increasingly important as biotechnology companies seek accelerated development timelines under financial and clinical pressure. OXB introduced a fast-track development and manufacturing offering for lentiviral and AAV programmes intended to reduce timelines to GMP manufacturing through platform-based development approaches and integrated manufacturing processes.
Commercial Manufacturing and Regulatory Support
Regulatory compliance remains a defining requirement within cell and gene therapy manufacturing as therapies move toward commercialisation across multiple jurisdictions. OXB integrates regulatory support into its manufacturing operations, supporting clients through IND, BLA and MAA submission processes alongside GMP production activities.
Manufacturing scale and facility infrastructure also continue to influence commercialisation strategies within advanced therapies. OXB operates manufacturing and development facilities across Oxfordshire in the UK, Lyon and Strasbourg in France, alongside sites in Bedford, Massachusetts and Durham, North Carolina. This footprint supports manufacturing proximity to major clinical and commercial markets while enabling production continuity across regions.
Commercial manufacturing increasingly requires alignment between production scalability, process transfer and long-term supply reliability. OXB supports technology transfer activities for programmes moving between development phases or transferring manufacturing into commercial-scale production environments.
Partnership activity continues to shape OXB’s operational expansion. It has worked with biotechnology and pharmaceutical companies developing therapies across oncology, rare disease and respiratory indications. In 2025, the company announced that its lentiviral vector manufacturing technology would support Boehringer Ingelheim’s Phase I and II gene therapy programme targeting cystic fibrosis.
As cell and gene therapy programmes expand toward broader clinical and commercial use, demand for scalable viral vector manufacturing, regulatory alignment and reliable production systems is expected to increase. OXB continues to expand its manufacturing and development capabilities to support these evolving industry requirements.
